Bexarotene low-dose maintenance for CTCL responders (75-150 mg/m² PO daily)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-BEXAROTENE`

ID	`REG-BEXAROTENE-MAINTENANCE-CTCL`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-CTCL-2024` `SRC-NCCN-BCELL-2025`

Notes

Maintenance dosing extends responses beyond induction. Same toxicity profile as induction dose but typically lower-grade — many patients remain on indefinite maintenance with periodic dose adjustment. Maintenance dose can also be used after response to mogamulizumab or BV induction as relapse-prevention strategy.

Used By

Indication

IND-MF-MAINTENANCE-RETINOID - IND-MF-MAINTENANCE-RETINOID